美国前列腺特异性抗原检测共同决策的近期模式
该研究利用2010年和2015年美国国家健康访谈调查数据,回顾性分析50岁及以上男性接受前列腺特异性抗原(PSA)检测时共同决策的变化。结果显示,近期检测者中报告至少一项共同决策要素的比例从58.5%升至62.6%,但差异无统计学意义;完全共同决策比例显著增加,仅告知优势的比例显著下降。未检测者中约10%报告至少一项共同决策要素,且无时间变化。
要点
- 2010至2015年,近期PSA检测男性中共同决策总体未显著增加。
- 完全共同决策(告知优势、劣势和不确定性)比例显著上升。
- 仅告知PSA检测优势的比例显著下降。
核心结论
- 2010至2015年间,近期接受PSA检测的男性中共同决策总体未增加,但模式从仅告知优势转向完全共同决策。
- 许多接受PSA检测的男性未获得共同决策。
研究设计与样本
- 回顾性横断面研究,使用2010年和2015年美国国家健康访谈调查(NHIS)数据,纳入50岁及以上男性共9598人。
- 分析按PSA检测状态(近期检测或无检测)分层,共同决策变化以调整后患病率比(aPR)和95%置信区间(CI)表示。
主要发现
- 近期检测男性中,仅被告知PSA检测优势的比例显著下降(aPR=0.82;95%CI 0.71-0.96)。
- 近期检测男性中,完全共同决策 prevalence 显著增加(aPR=1.51;95%CI 1.28-1.79)。
- 无 prior PSA检测男性中,约10%报告至少一项共同决策要素,且随时间无变化。
关键数值与推荐
- 共同决策要素包括:仅告知优势、告知优势与劣势、完全共同决策(优势、劣势和不确定性)。
- 近期PSA检测定义为过去一年内检测。
临床怎么用
- 全科医生在PSA检测决策中应实施完全共同决策,涵盖优势、劣势和不确定性。
- 需关注未检测男性中共同决策覆盖不足的问题。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Previous studies report infrequent use of shared decision making for prostate-specific antigen (PSA) testing. It is unknown whether this pattern has changed recently considering increased emphasis on shared decision making in prostate cancer screening recommendations. Thus, the objective of this study is to examine recent changes in shared decision making. METHODS: We conducted a retrospective cross-sectional study among men aged 50 years and older in the United States using 2010 and 2015 National Health Interview Survey (NHIS) data (n = 9,598). Changes in receipt of shared decision making were expressed as adjusted prevalence ratios (aPR) and 95% confidence intervals (CI). Analyses were stratified on PSA testing (recent [in the past year] or no testing). Elements of shared decision making assessed included the patient being informed about the advantages only, advantages and disadvantages, and full shared decision making (advantages, disadvantages, and uncertainties). RESULTS: Among men with recent PSA testing, 58.5% and 62.6% reported having received ≥1 element of shared decision making in 2010 and 2015, respectively (P = .054, aPR = 1.04; 95% CI, 0.98-1.11). Between 2010 and 2015, being told only about the advantages of PSA testing significantly declined (aPR = 0.82; 95% CI, 0.71-0.96) and full shared decision making prevalence significantly increased (aPR = 1.51; 95% CI, 1.28-1.79) in recently tested men. Among men without prior PSA testing, 10% reported ≥1 element of shared decision making, which did not change with time. CONCLUSION: Between 2010 and 2015, there was no increase in shared decision making among men with recent PSA testing though there was a shift away from only being told about the advantages of PSA testing towards full shared decision making. Many men receiving PSA testing did not receive shared decision making.
引用
- Fedewa SA, Gansler T, Smith R, et al. Recent Patterns in Shared Decision Making for Prostate-Specific Antigen Testing in the United States. Ann Fam Med. 2018. PMID: 29531105. doi:10.1370/afm.2200
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。